Format

Send to

Choose Destination
Sci Rep. 2016 May 25;6:26511. doi: 10.1038/srep26511.

Engineering the Campylobacter jejuni N-glycan to create an effective chicken vaccine.

Author information

1
Department of Biological Sciences, University of Alberta, Edmonton, Canada.
2
Alberta Glycomics Centre, University of Alberta, Edmonton, Canada.
3
Delta Genomics, Edmonton, Canada.
4
Department of Agricultural, Food &Nutritional Science, University of Alberta, Edmonton, Canada.
5
Human Health Therapeutics, National Research Council, Ottawa, Canada.

Abstract

Campylobacter jejuni is a predominant cause of human gastroenteritis worldwide. Source-attribution studies indicate that chickens are the main reservoir for infection, thus elimination of C. jejuni from poultry would significantly reduce the burden of human disease. We constructed glycoconjugate vaccines combining the conserved C. jejuni N-glycan with a protein carrier, GlycoTag, or fused to the Escherichia coli lipopolysaccharide-core. Vaccination of chickens with the protein-based or E. coli-displayed glycoconjugate showed up to 10-log reduction in C. jejuni colonization and induced N-glycan-specific IgY responses. Moreover, the live E. coli vaccine was cleared prior to C. jejuni challenge and no selection for resistant campylobacter variants was observed. Analyses of the chicken gut communities revealed that the live vaccine did not alter the composition or complexity of the microbiome, thus representing an effective and low-cost strategy to reduce C. jejuni in chickens and its subsequent entry into the food chain.

PMID:
27221144
PMCID:
PMC4879521
DOI:
10.1038/srep26511
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center